Filtered By:
Source: The Journal of Heart and Lung Transplantation
This page shows you your search results in order of relevance. This is page number 12.
Order by Relevance | Date
Total 231 results found since Jan 2013.
Comparison of Bridge-to-Transplant Outcomes with HeartMate 3 and HeartMate II Left Ventricular Assist Devices: A UNOS Registry Analysis
The Momentum 3 trial established the noninferiority of the HeartMate 3 (HM3) left ventricular assist device (LVAD) compared to HeartMate II (HM2) for survival free of disabling stroke or need for surgical intervention due to LVAD malfunction- leading to FDA approval of HM3 for bridge-to-transplant (BTT) and destination therapy. Heart transplant (HT) waitlist outcomes have not specifically been compared between HM3 and HM2.
Source: The Journal of Heart and Lung Transplantation - March 16, 2019 Category: Transplant Surgery Authors: R.C. Givens, S.M. Kochav, P.C. Colombo, M.A. Farr, S.W. Restaino, V.K. Topkara Tags: 868 Source Type: research
Preoperative Computational Fluid Dynamics Simulation of the Best Anastomosis Site and Angle of the Outflow Graft and Ascending Aorta in Continuous Flow Mechanical Assist Devices
Left ventricle assist devices (LVAD) have contributed to improve survival and quality of life in patients with advanced heart failure, in temporary or lifetime support. Despite technological, bio-compatibility and hemodynamic progress, patients with LVAD have still a relevant incidence of adverse events, such as disabling stroke. The outflow cannula (OC) position and angulation, and the anastomosis site seem to modify the flow in the ascending aorta (AA), and consequently the incidence of cerebral embolism and aortic cusps stress.
Source: The Journal of Heart and Lung Transplantation - March 16, 2019 Category: Transplant Surgery Authors: A. Giacomini, A. Esposito, T. Nisi, E. Lapenna, S. Bartesaghi, D. Redaelli, F. Pappalardo, G. Colombo, M. De Bonis Tags: 863 Source Type: research
Mechanical Circulatory Support Patients Awaiting Heart Transplant with Positive AT1R Antibodies Have Acceptable Outcome Post-Heart Transplant
AT1R antibodies (Abs) are known to occur in patients (pts) with heart failure. It has been reported that when AT1R Abs are detected at high levels in mechanical circulatory support (MCS) pts, MCS mortality is increased. AT1R has been associated with the development of an inflammatory state inciting thrombosis. It may be that AT1R Abs are associated with pump thrombosis or even possibly thrombotic stroke. Furthermore, it is not clear whether these pts with MCS and AT1R Abs are at increased risk for post-heart transplant complications such as primary graft dysfunction (PGD) due to the recipients ’ highly inflamed state whi...
Source: The Journal of Heart and Lung Transplantation - March 16, 2019 Category: Transplant Surgery Authors: D.H. Chang, J. Patel, M. Kittleson, D. Geft, S. Dimbil, R. Levine, C. Kawata, L. Czer, J. Moriguchi, D. Ramzy, J.A. Kobashigawa Tags: 502 Source Type: research
It Takes a Village: Pediatric Ventricular Assist Device Training and Education Practices among ACTION Centers
The last decade has seen a dramatic increase in the number of ventricular assist devices (VADs) implanted in children. Despite the increases, the procedure remains uncommon at individual centers making patient, family and staff education challenging. ACTION (Advanced Cardiac Therapies Improving Outcomes Network) is the first pediatric VAD quality improvement network. The initial goal of ACTION is stroke reduction. We sought to describe the education and care delivery structure among members of the ACTION pediatric VAD quality improvement collaborative.
Source: The Journal of Heart and Lung Transplantation - March 16, 2019 Category: Transplant Surgery Authors: K. Fields, B. Hawkins, J. Lantz, M. Mehegan, J. Murray, L. Burkhart, C. Villa Tags: 471 Source Type: research
Does Left Atrial Appendage Occlusion in LVAD Patients Impact Outcomes: A Single Centre Study
Results of left atrial appendage occlusion (LAAO) in coronary artery bypass and valvular surgeries from large multicentre studies remain contradictory. No data has been presented on the outcomes of LAAO during left ventricular assist device (LVAD) implant. Therefore, we studied the effects of LAAO during LVAD implantation on postoperative risk of stroke and mortality.
Source: The Journal of Heart and Lung Transplantation - March 16, 2019 Category: Transplant Surgery Authors: F. Yu, J. Alvarez, R. Ribeiro, M.B. Adamson, F. Amin, M. Degen, F. Foroutan, J. Duero Posada, T. Yau, R. Cusimano, F. Billia, C. Alba, M. Badiwala, V. Rao Tags: 404 Source Type: research
Digoxin is Associated with Decreased Survival Free from Hemocompatibility-Related Adverse Events in LVAD Patients - A Propensity Score Matched Analysis
Hemocompatibility-related adverse events (HRAEs) (stroke, suspected pump thrombosis (sPT), gastrointestinal bleeding (GIB)) reduce survival and quality of life in LVAD pts. The association between pharmacotherapy and both HRAEs and survival is poorly characterized. We aimed to assess this association in HeartMate II (HMII) pts.
Source: The Journal of Heart and Lung Transplantation - March 16, 2019 Category: Transplant Surgery Authors: A. Pinsino, A. Gaudig, K.L. Hoffman, D. D'Angelo, E.A. Royzman, G.M. Mondellini, F. Castagna, A.M. Zuver, A.R. Garan, H. Takayama, K. Takeda, Y. Naka, R.T. Demmer, M. Yuzefpolskaya, P.C. Colombo Tags: 397 Source Type: research
A Trial of Complete Withdrawal of Anticoagulation Therapy in the Heartmate 3 Pump
The HeartMate 3 Left Ventricular Assist System has demonstrated absence of confirmed de-novo pump thrombosis and reduction in stroke. However, bleeding related adverse events persist under standard anticoagulation targeting a INR range of 2.0-3.0. In an initial experience we demonstrated safety of transition to low intensity anticoagulation (INR target 1.5-1.9, n=15, follow up of at least 6 months). Whether complete cessation of anticoagulation maintains “thromboresistance” in the HeartMate 3 pump remains unknown.
Source: The Journal of Heart and Lung Transplantation - March 16, 2019 Category: Transplant Surgery Authors: I. Netuka, P. Ivak, Z. Tucanova, S. Gregor, O. Szarszoi, J. Rimsans, J. Connors, D. Crandall, P. Sood, M. Mehra Tags: 254 Source Type: research
A Comparison of Middle Cerebral Artery and Central Retinal Artery Hemodynamics in HM II Patients
In the normal, pulsatile circulation, the hemodynamic pattern of the middle cerebral artery (MCA) differs from the central retinal artery (CRA). Whether continuous flow from a left ventricular assist device (LVAD) alters this relationship is not known. Since serious adverse events in different end-organs, such as stroke and GI bleeding, are frequent in LVAD patients, comparing hemodynamics in different arterial beds may enhance our understanding of the specific pathophysiology of these complications.
Source: The Journal of Heart and Lung Transplantation - March 16, 2019 Category: Transplant Surgery Authors: E.J. St öhr, R. Ji, K. Akiyama, F. Castagna, A. Pinsino, J.R. Cockcroft, M. Yuzefpolskaya, A.R. Garan, V.K. Topkara, R.T. Te-Frey, H. Takayama, K. Takeda, Y. Naka, P.C. Colombo, J.Z. Willey, B.J. McDonnell Tags: 200 Source Type: research
Presence of Left Atrial or Left Ventricular Thrombus at the Time of CF-LVAD Implantation is Associated with Increased Post-Operative Risk of Stroke or Death
Patients with advanced HF are at increased risk for intra-cardiac thrombus formation. The impact of pre-existing left atrial (LA) or left ventricular (LV) thrombi on post-operative outcomes in LVAD patients is unknown.
Source: The Journal of Heart and Lung Transplantation - March 16, 2019 Category: Transplant Surgery Authors: J.A. Fried, H. Lumish, A.M. Zuver, A.R. Garan, V.K. Topkara, B. Cagliostro, G. Parkis, M. Cevasco, M.T. Pineda, G.M. Mondellini, K. Ross, L. Witer, H. Takayama, K. Takeda, Y. Naka, M. Yuzefpolskaya, R.T. Demmer, P.C. Colombo Tags: 147 Source Type: research
Cessation of Anticoagulation for Bleeding and Thrombosis Events with a Fully Magnetically Levitated Centrifugal Left Ventricular Assist Device
Anticoagulation therapy for patients supported by a left ventricular assist device (LVAD) has not been adequately evaluated in relevance to newer pumps, such as the fully magnetically levitated HeartMate 3 pump. Current anticoagulation guidelines target a goal INR of 2.0 –3.0 with vitamin K antagonists to mitigate the risk of pump thrombosis and ischemic stroke, but are based on historical trials with older devices. Long-term outcomes associated with newer devices, such as the centrifugal-flow HeartMate 3 (HM3), have demonstrated a marked decrease in the incidence of pump thrombosis compared to mechanical bearing axial-f...
Source: The Journal of Heart and Lung Transplantation - April 28, 2019 Category: Transplant Surgery Authors: Igor Gosev, Brian Ayers, Katherine Wood, Bryan Barrus, Sunil Prasad Tags: Case Anecdotes, Comments and Opinions Source Type: research
Cessation of anti-coagulation for bleeding and subsequent thrombosis events with a fully magnetically levitated centrifugal left ventricular assist device
Anti-coagulation therapy for patients supported by a left ventricular assist device (LVAD) has not been adequately evaluated in relevance to newer pumps, such as the fully magnetically levitated HeartMate 3 (HM3) pump. Current anti-coagulation guidelines target a goal international normalized ratio (INR) of 2.0 to 3.0, with vitamin K antagonists to mitigate the risk of pump thrombosis and ischemic stroke, but are based on historical trials with older devices. Long-term outcomes associated with newer devices, such as the centrifugal-flow HM3, have demonstrated a marked decrease in the incidence of pump thrombosis compared w...
Source: The Journal of Heart and Lung Transplantation - April 28, 2019 Category: Transplant Surgery Authors: Igor Gosev, Brian Ayers, Katherine Wood, Bryan Barrus, Sunil Prasad Tags: CASE ANECDOTES, COMMENTS AND OPINIONS Source Type: research
Peripheral Component Malfunction of a Fully Magnetically Levitated Centrifugal Pump Masquerading as Pump Thrombosis
We present the case of a HM-3 controller malfunction, resembling pump thrombosis based on acute changes to pump parameters and abnormal LVAD log file analysis.
Source: The Journal of Heart and Lung Transplantation - June 18, 2019 Category: Transplant Surgery Authors: Ioannis Mastoris, Mohamed El Khashab, Travis Abicht Tags: CASE ANECDOTES, COMMENTS AND OPINIONS Source Type: research
Ventricular Assist Device Deactivation in Children: Preparedness Planning and Procedural Checklist
Key difference exist between adult and pediatric Ventricular Assist Device (VAD) care. For many adult patients, VADs are commonly implanted as destination therapy in contrast to pediatric patients who more often receive VAD therapy as a bridge to transplant. Adult patients/families may be better prepared for the anticipated and enivadable complications that occur at the end of destination therapy, but receive benefit from VAD therapy for both prolonged quantity and quality of life. Despite the success of VAD as a bridge to heart transplantation in children, adverse and debilitating events, including stroke, thrombosis, inf...
Source: The Journal of Heart and Lung Transplantation - June 18, 2019 Category: Transplant Surgery Authors: Desiree S. Machado, Seth A. Hollander, Jenna Murray, Joseph Philip, Mark Bleiweis, Sheri Kittelson Tags: Letter to the Editor Source Type: research
First Human Implantation of A Miniaturized Axial Flow Ventricular Assist Device in a Child with End-Stage Heart Failure
Small children with end-stage heart failure who require left ventricular assist device (LVAD) support to heart transplant have limited device options leading to high morbidity and mortality and chronic hospitalization until transplant.1,2 The only FDA-approved durable LVAD for children is a paracorporeal pulsatile device that carries a high stroke risk and lacks portability precluding hospital discharge.1 Temporary paracorporeal continuous flow (CF) devices have also been used off-label for bridge-to-transplant but carry higher mortality, require lengthy paracorporeal cannulas prone to circuit thrombus, and typically requi...
Source: The Journal of Heart and Lung Transplantation - September 10, 2019 Category: Transplant Surgery Authors: Antonio Amodeo, Sergio Filippelli, Gianluigi Perri, Roberta Iacobelli, Rachele Adorisio, Francesca Iodice, Alessandra Rizza, M. Patricia Massicotte, J. Timothy Baldwin, Christopher S.D. Almond Tags: Case Anecdotes, Comments and Opinions Source Type: research
This is Your Brain on LVAD
The utilization and duration of left ventricular assist device (LVAD) support has increased steadily over the last decade and recent changes in the UNOS heart allocation system, implemented in October 2018, portend a further increase in the duration of mechanical circulatory support for many patients (1). Though four-year survival rates have improved to 60% following LVAD implantation, the leading cause of death in these patients is neurological injury, specifically ischemic and hemorrhagic stroke (spontaneous subarachnoid hemorrhage or intraparenchymal hemorrhage [IPH]) (2).
Source: The Journal of Heart and Lung Transplantation - January 24, 2020 Category: Transplant Surgery Authors: Jennifer A. Frontera Tags: Editorial Source Type: research
